Contact
searchSearch
HMP Global
Escaned and Sandoval
CT-Guided PCI at TCT 2026
Reactions to the International Randomized P4 (Precise Procedural and PCI Plan) Trial
11/06/2026
Javier Escaned, MD, PhD; Yader Sandoval, MD
Professors Javier Escaned and Yader Sandoval, interventional cardiologists experienced in CT-guided PCI, share their thoughts on the P4 trial.
Professors Javier Escaned and Yader Sandoval, interventional cardiologists experienced in CT-guided PCI, share their thoughts on the P4 trial.
Professors Javier Escaned and...
11/06/2026
Cath Lab Digest
Nicole Dellise and Derek Pineda
For the CV Team
The Importance of Publishing — and Pathways to Follow — For the CV Team
11/05/2026
Nicole Dellise, DNP, FNP-BC, NEA-BC, CHFN, CCK, FACC; Derek Pineda, FNP, CCRN, RCIS
Nicole Dellise, DNP, and Derek Pineda, FNP, describe their recent publication encouraging cardiovascular team members to publish and the importance of sharing their work with the broader community.
Nicole Dellise, DNP, and Derek Pineda, FNP, describe their recent publication encouraging cardiovascular team members to publish and the importance of sharing their work with the broader community.
Nicole Dellise, DNP, and Derek...
11/05/2026
Cath Lab Digest
Derek Pineda, FNP, CCRN, RCIS
TCT Nurse & Technologist Symposium
Beyond the Stent: Metal-Free Coronary Revascularization
11/05/2026
Derek Pineda, FNP, CCRN, RCIS
Derek Pineda, FNP, CCRN, RCIS, AACC, shares thoughts from his presentation on drug-coated balloons at the TCT Nurse and Technologist Symposium, which took place in San Diego, California, on October 31, 2026. 
Derek Pineda, FNP, CCRN, RCIS, AACC, shares thoughts from his presentation on drug-coated balloons at the TCT Nurse and Technologist Symposium, which took place in San Diego, California, on October 31, 2026. 
Derek Pineda, FNP, CCRN, RCIS,...
11/05/2026
Cath Lab Digest
Women and PE
SYMPHONY-PE IDE: First-in-Field Analysis Provides Encouraging Safety Findings for Women with Pulmonary Embolism
11/04/2026
Sub-analysis presented at TCT 2026 shows substantial clot burden reduction and improved right-heart function with the Symphony Thrombectomy System despite greater baseline cardiac stress in women
Sub-analysis presented at TCT 2026 shows substantial clot burden reduction and improved right-heart function with the Symphony Thrombectomy System despite greater baseline cardiac stress in women
Sub-analysis presented at TCT...
11/04/2026
Cath Lab Digest
Renal Denervation
TCT26: Renal Denervation with Medtronic Symplicity Shows Significant Blood Pressure Drops in SPYRAL AFFIRM Real-World Study
11/04/2026
Nearly nine out of 10 patients experienced a clinical benefit at six months. Medtronic receives FDA approval for U.S. labeling update to Symplicity blood pressure procedure, expanding clinical evidence informing treatment options
Nearly nine out of 10 patients experienced a clinical benefit at six months. Medtronic receives FDA approval for U.S. labeling update to Symplicity blood pressure procedure, expanding clinical evidence informing treatment options
Nearly nine out of 10 patients...
11/04/2026
Cath Lab Digest
TAVR
TAVR Use Increased Nearly Ninefold Among Patients Under 70 in Health System Analysis
11/04/2026
Annual TAVR procedures among patients younger than 70 rose from 15 in 2014 to 134 in 2024 within one health system, driven primarily by patients in their 60s, while surgery remained predominant.
Annual TAVR procedures among patients younger than 70 rose from 15 in 2014 to 134 in 2024 within one health system, driven primarily by patients in their 60s, while surgery remained predominant.
Annual TAVR procedures among...
11/04/2026
Cath Lab Digest
Vertex Catheter (Jupiter Endovascular)
Pulmonary Embolism
New SPIRARE II Data at TCT 2026 Show Restoring Normal Pulmonary Pressure Using Vertex System Tracked with Right Heart Recovery in Pulmonary Embolism
11/03/2026
Post-hoc analysis presented by Dr. Sripal Bangalore also found reaching lower lobes of lungs was associated with greater hemodynamic restoration without added safety concerns.
Post-hoc analysis presented by Dr. Sripal Bangalore also found reaching lower lobes of lungs was associated with greater hemodynamic restoration without added safety concerns.
Post-hoc analysis presented by...
11/03/2026
Cath Lab Digest
renal denervation
Paradise uRDN System Demonstrates 19.5 mmHg Blood Pressure Reduction at 12 Months, with Durability Through 4 Years
11/03/2026
Seven abstracts sponsored by Recor Medical presented at TCT 2026 highlight expanding clinical evidence for ultrasound renal denervation.
Seven abstracts sponsored by Recor Medical presented at TCT 2026 highlight expanding clinical evidence for ultrasound renal denervation.
Seven abstracts sponsored by...
11/03/2026
Cath Lab Digest
transcatheter heart valves
Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026
11/03/2026
Anteris Technologies Global Corp. announced 30-day clinical and hemodynamic outcomes for the Medium-size DurAVR® Transcatheter Heart Valve (THV) in twenty-two severe aortic stenosis patients with medium aortic annuli (aortic annulus area 492...
Anteris Technologies Global Corp. announced 30-day clinical and hemodynamic outcomes for the Medium-size DurAVR® Transcatheter Heart Valve (THV) in twenty-two severe aortic stenosis patients with medium aortic annuli (aortic annulus area 492...
Anteris Technologies Global...
11/03/2026
Cath Lab Digest
radiation safety
Lead-Free Shielding System Associated with Low Operator Radiation Exposure During Endovascular Procedures
11/02/2026
Multicenter study reports low operator radiation exposure across 95 sites using an alternative to traditional lead-apron protection.
Multicenter study reports low operator radiation exposure across 95 sites using an alternative to traditional lead-apron protection.
Multicenter study reports low...
11/02/2026
Cath Lab Digest
R-Star system (Robocath)
Robotic PCI
First-in-Human Coronary Intervention Study Results of Robocath’s Next-Generation Robotic System Highlighted at TCT
11/02/2026
The findings support a favorable performance profile for the system, with 100% clinical success rate and no device-related complications.
The findings support a favorable performance profile for the system, with 100% clinical success rate and no device-related complications.
The findings support a favorable...
11/02/2026
Cath Lab Digest
Left Atrial Appendage Occlusion
SIMPLAAFY Study: Less Intensive Antithrombotic Strategies Met Noninferiority Compared with DAPT After Left Atrial Appendage Closure
11/02/2026
New findings from the randomized SIMPLAAFY trial suggest that less intensive antithrombotic therapy following left atrial appendage closure (LAAC) with the WATCHMAN FLX™ Pro LAAC Device can reduce the risk of clinically-relevant bleeding...
New findings from the randomized SIMPLAAFY trial suggest that less intensive antithrombotic therapy following left atrial appendage closure (LAAC) with the WATCHMAN FLX™ Pro LAAC Device can reduce the risk of clinically-relevant bleeding...
New findings from the randomized...
11/02/2026
Cath Lab Digest
Tricuspid Valve Intervention
CLASP II TR Trial Demonstrates Superior Clinical, Quality-of-Life Benefits With Edwards PASCAL System
11/02/2026
Among the CLASP II TR patients treated with the PASCAL system, 80% achieved ≤ moderate TR at 1 year vs. 30% in the control group and showed a clinically significant 18-point improvement in patient quality-of-life measures as reported in the...
Among the CLASP II TR patients treated with the PASCAL system, 80% achieved ≤ moderate TR at 1 year vs. 30% in the control group and showed a clinically significant 18-point improvement in patient quality-of-life measures as reported in the...
Among the CLASP II TR patients...
11/02/2026
Cath Lab Digest
degenerative mitral valve disease
Global Burden of Degenerative Mitral Valve Disease Doubled Over 30 Years, with Worse Outcomes in Women and Low-Resource Areas
11/02/2026
In this analysis, the global prevalence of DMVD increased over the 30-year period by 126% to an estimated 16.1 million individuals, while deaths increased by 75% to 39,800. However, the age-standardized prevalence rate remained relatively...
In this analysis, the global prevalence of DMVD increased over the 30-year period by 126% to an estimated 16.1 million individuals, while deaths increased by 75% to 39,800. However, the age-standardized prevalence rate remained relatively...
In this analysis, the global...
11/02/2026
Cath Lab Digest
TAVR for Moderate AS
PROGRESS Trial: TAVR Improves Outcomes for Patients with Moderate Aortic Stenosis and At-Risk Features
11/02/2026
In a randomized trial of patients with moderate AS and at least one at-risk feature, those who underwent earlier TAVR had improved outcomes at two years than those managed with clinical surveillance.
In a randomized trial of patients with moderate AS and at least one at-risk feature, those who underwent earlier TAVR had improved outcomes at two years than those managed with clinical surveillance.
In a randomized trial of...
11/02/2026
Cath Lab Digest
Left Atrial Appendage Occlusion
VERITAS: Late-Breaking One-Year Data Show Abbott's Next-Generation Amulet 360™ Device Continues to Demonstrate High Rates of Left Atrial Appendage Closure and Low Incidence of Stroke
11/02/2026
Late-breaking one-year VERITAS study results were presented at TCT 2026; data show the device achieved high closure rates of the left atrial appendage (LAA) and a low incidence of stroke.
Late-breaking one-year VERITAS study results were presented at TCT 2026; data show the device achieved high closure rates of the left atrial appendage (LAA) and a low incidence of stroke.
Late-breaking one-year VERITAS...
11/02/2026
Cath Lab Digest
Electrocardiograms: AI
ALIGN-ACS: HeartBeam Announces Positive Heart Attack Pilot Study Results – Patient-Recorded 3D ECG Shown to Be as Accurate as Standard 12-Lead ECG
11/02/2026
HeartBeam’s portable, cable-free, credit-card-sized device enables patients to record their own ECG on-demand, wherever they are, including at home. Unlike conventional wearables, HeartBeam captures three-dimensional electrical information...
HeartBeam’s portable, cable-free, credit-card-sized device enables patients to record their own ECG on-demand, wherever they are, including at home. Unlike conventional wearables, HeartBeam captures three-dimensional electrical information...
HeartBeam’s portable,...
11/02/2026
Cath Lab Digest
Aortic Stenosis: AI
TCT 2026 Clinical Data Reveals 84% Reporting Gap in Aortic Valve Calcification, Highlighting the Potential of Nanox.AI’s AVC Solution
11/02/2026
Nanox.AI's Investigational AVC Solution Demonstrated 98.3% Sensitivity and 96.6% Specificity in Evaluable CT Scans. Findings Highlight the Potential of AI to Identify Previously Unreported Aortic Valve Calcification Using Existing Routine CT...
Nanox.AI's Investigational AVC Solution Demonstrated 98.3% Sensitivity and 96.6% Specificity in Evaluable CT Scans. Findings Highlight the Potential of AI to Identify Previously Unreported Aortic Valve Calcification Using Existing Routine CT...
Nanox.AI's Investigational AVC...
11/02/2026
Cath Lab Digest
CLINICAL Trials: LAAO
Late-Breaking One-Year Data Show Abbott’s Next-Gen Amulet 360 Device Continues to Demonstrate High Rates of Left Atrial Appendage Closure and Low Incidence of Stroke
11/02/2026
Late-breaking one-year VERITAS study results were presented at the Transcatheter Cardiovascular Therapeutics conference and simultaneously published in JACC: Cardiovascular Interventions; data show the device achieved high closure rates of...
Late-breaking one-year VERITAS study results were presented at the Transcatheter Cardiovascular Therapeutics conference and simultaneously published in JACC: Cardiovascular Interventions; data show the device achieved high closure rates of...
Late-breaking one-year VERITAS...
11/02/2026
Cath Lab Digest
Hybrid OCT-IVUS Imaging
Conavi Medical Completes First U.S. Commercial Placement and Clinical Cases with its OCTIV Hybrid Imaging System to Guide Coronary Interventions
11/02/2026
The placement and first cases mark a milestone in Conavi’s targeted U.S. commercial rollout following FDA 510(k) clearance.
The placement and first cases mark a milestone in Conavi’s targeted U.S. commercial rollout following FDA 510(k) clearance.
The placement and first cases...
11/02/2026
Cath Lab Digest
Cristina Valdez MSN ACNP
TCT Nurse & Technologist Symposium
Calcium Modification at TCT's Nurse & Technologist Symposium
11/02/2026
Cristina Valdez, MSN, ACNP
Cristina Valdez, MSN, ACNP, presented "Cursed Vessels: Navigating the Nightmare of Coronary Calcification" at the October 31st Nurse and Technologist session at TCT 2026 in San Diego, California.
Cristina Valdez, MSN, ACNP, presented "Cursed Vessels: Navigating the Nightmare of Coronary Calcification" at the October 31st Nurse and Technologist session at TCT 2026 in San Diego, California.
Cristina Valdez, MSN, ACNP,...
11/02/2026
Cath Lab Digest
clinical trial: IVL
FORWARD CAD IDE: Shockwave Javelin Coronary IVL Catheter Delivers Positive Results in Pivotal Study
11/01/2026
30-day data from the FORWARD CAD IDE study demonstrate favorable safety and efficacy outcomes for the Shockwave Javelin Coronary Intravascular Lithotripsy (IVL) catheter when used to modify highly stenosed, challenging calcific coronary...
30-day data from the FORWARD CAD IDE study demonstrate favorable safety and efficacy outcomes for the Shockwave Javelin Coronary Intravascular Lithotripsy (IVL) catheter when used to modify highly stenosed, challenging calcific coronary...
30-day data from the FORWARD CAD...
11/01/2026
Cath Lab Digest
Clinical Trials: PE
Mechanical Thrombectomy Linked to Lower Mortality in Intermediate-Risk Pulmonary Embolism
11/01/2026
In the primary analysis, mechanical thrombectomy was associated with lower 30-day, 1-year, and 2-year mortality, as well as a lower risk of chronic thromboembolic pulmonary hypertension.
In the primary analysis, mechanical thrombectomy was associated with lower 30-day, 1-year, and 2-year mortality, as well as a lower risk of chronic thromboembolic pulmonary hypertension.
In the primary analysis,...
11/01/2026
Cath Lab Digest
Annapoorna S. Kini, MD, Director of the Cardiac Catheterization Lab at The Mount Sinai Hospital, and the Zena and Michael A. Wiener Professor of Medicine at the Icahn School of Medicine at Mount Sinai leads the NODULE-SHOCK trial.
Clinical Trials: IVL + RA
NODULE-SHOCK: New Treatment Approach for Calcified Nodules Shown to Improve Coronary Stent Expansion in Mount Sinai Clinical Trial
11/01/2026
Study results show combining two techniques can increase stent area by 19 percent and lead to improved patient outcomes.
Study results show combining two techniques can increase stent area by 19 percent and lead to improved patient outcomes.
Study results show combining two...
11/01/2026
Cath Lab Digest
Clinical Trials: IVL
Abbott’s TECTONIC Clinical Trial Demonstrates Strong 30-Day Outcomes and High Procedural Success for Its Investigational SonicForce Coronary Intravascular Lithotripsy System
11/01/2026
The study met its primary safety and effectiveness endpoints, demonstrating excellent early clinical outcomes in patients with severe coronary calcification.
The study met its primary safety and effectiveness endpoints, demonstrating excellent early clinical outcomes in patients with severe coronary calcification.
The study met its primary safety...
11/01/2026
Cath Lab Digest
clinical trials: coronary sinus reducer
REMEDY-PILOT: First Sham-Controlled Study Shows No Improvements after Coronary Sinus Reducer in Patients with Refractory Angina and Unobstructed Coronary Arteries
11/01/2026
Coronary sinus reducer (CSR) implantation was safe but did not significantly improve myocardial perfusion reserve (MPR), patient-reported symptoms, or quality of life in patients with coronary microvascular dysfunction (CMD) and refractory...
Coronary sinus reducer (CSR) implantation was safe but did not significantly improve myocardial perfusion reserve (MPR), patient-reported symptoms, or quality of life in patients with coronary microvascular dysfunction (CMD) and refractory...
Coronary sinus reducer (CSR)...
11/01/2026
Cath Lab Digest
Clinical Trials: Heparin Dosing
HD-PCI: Higher-Dose Heparin Does Not Provide Appreciable Benefit Over Lower-Dose Strategy During PCI
11/01/2026
New results from the HD-PCI study show that a higher-dose unfractionated heparin (UFH) regimen did not improve clinical outcomes compared with a lower-dose strategy during percutaneous coronary intervention (PCI).
New results from the HD-PCI study show that a higher-dose unfractionated heparin (UFH) regimen did not improve clinical outcomes compared with a lower-dose strategy during percutaneous coronary intervention (PCI).
New results from the HD-PCI...
11/01/2026
Cath Lab Digest
Clinical Trials: Sirolimus-Coated Balloon
TRANSFORM II: Sirolimus-Coated Balloon Appears to be a Comparable Alternative to a Drug-Eluting Stent in Previously Untreated Native Coronary Vessels
11/01/2026
Results from the open-label, randomized, noninferiority TRANSFORM II trial demonstrated noninferiority of a sirolimus-coated balloon (SCB) strategy to everolimus drug-eluting stents (EES) after successful lesion preparation in patients with...
Results from the open-label, randomized, noninferiority TRANSFORM II trial demonstrated noninferiority of a sirolimus-coated balloon (SCB) strategy to everolimus drug-eluting stents (EES) after successful lesion preparation in patients with...
Results from the open-label,...
11/01/2026
Cath Lab Digest
DEEPER CORONARY trial
First-in-Human Pilot Study
Reflow Medical Reports One-Year Results from DEEPER CORONARY Study of Investigational Coronary Spur Elute Sirolimus-Eluting Retrievable Stent System
11/01/2026
The coronary Spur Elute is designed to create microchannels that facilitate drug delivery into the vessel wall, complemented by direct contact sirolimus transfer from the drug- coated scaffold struts and integrated balloon.
The coronary Spur Elute is designed to create microchannels that facilitate drug delivery into the vessel wall, complemented by direct contact sirolimus transfer from the drug- coated scaffold struts and integrated balloon.
The coronary Spur Elute is...
11/01/2026
Cath Lab Digest
mechanical circulatory support devices
Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results
11/01/2026
Analyses presented at TCT highlight how patient selection, timely Impella support and consistent care protocols may help improve outcomes during and after complex heart procedures.
Analyses presented at TCT highlight how patient selection, timely Impella support and consistent care protocols may help improve outcomes during and after complex heart procedures.
Analyses presented at TCT...
11/01/2026
Cath Lab Digest
DeepOCT+NIRS
Imaging + Physiology Integration
Philips Launches HyperVue Integrated System in the U.S., Bringing Advanced Coronary Imaging and Physiology Into the Cath Lab
10/31/2026
New fixed, single-room configuration is designed to make DeepOCT+NIRS Imaging and X1-FFR physiology readily available for efficient cath lab workflows.
New fixed, single-room configuration is designed to make DeepOCT+NIRS Imaging and X1-FFR physiology readily available for efficient cath lab workflows.
New fixed, single-room...
10/31/2026
Cath Lab Digest
moderate AS: clinical trial
Medtronic Presents Evolut EXPAND TAVR II Trial Design and Baseline Characteristics of Patients With Moderate Aortic Stenosis at TCT 2026
10/31/2026
Featured clinical science presentation highlights global randomized trial investigating TAVR intervention alongside guideline-directed medical therapy.
Featured clinical science presentation highlights global randomized trial investigating TAVR intervention alongside guideline-directed medical therapy.
Featured clinical science...
10/31/2026
Cath Lab Digest
mechanical circulatory support devices
Record 26 Abstracts at TCT 2026 Adds to More than 20 Years of Data Demonstrating the Safety, Efficacy and Cost Effectiveness of Impella Heart Pumps
10/30/2026
Impella clinical data being presented at TCT includes new research across high-risk percutaneous coronary intervention (HRPCI), cardiogenic shock, myocardial recovery, renal perfusion, physiologic risk and next-generation technology.
Impella clinical data being presented at TCT includes new research across high-risk percutaneous coronary intervention (HRPCI), cardiogenic shock, myocardial recovery, renal perfusion, physiologic risk and next-generation technology.
Impella clinical data being...
10/30/2026
Cath Lab Digest
Cath Lab Digest
5-Minute Overview
TCT 2026: Late-Breaking Trials and Clinical Science to Watch
10/15/2026
Rebecca Kapur, Managing Editor, CLD
A 5-minute overview of the TCT 2026 late-breaking trials likely to matter in the cath lab, from CT- and physiology-guided PCI to drug-coated balloons, transcatheter valve intervention, cerebral protection during TAVR, and renal denervation.
A 5-minute overview of the TCT 2026 late-breaking trials likely to matter in the cath lab, from CT- and physiology-guided PCI to drug-coated balloons, transcatheter valve intervention, cerebral protection during TAVR, and renal denervation.
A 5-minute overview of the TCT...
10/15/2026
Cath Lab Digest
Jay R. Khambhati, MD
Retrospective Analysis
Long-Term Clinical Outcomes After TAVR With Balloon-Expandable Versus Self-Expanding Valves
11/10/2023
Jay R. Khambhati, MD
Researchers compared longitudinal clinical outcomes in patients undergoing TAVR with balloon expandable versus self-expanding valves in patients who received either therapy from 2014 to 2020.
Researchers compared longitudinal clinical outcomes in patients undergoing TAVR with balloon expandable versus self-expanding valves in patients who received either therapy from 2014 to 2020.
Researchers compared...
11/10/2023
Cath Lab Digest
Dr. Josep Rodés-Cabau
Clinical Trial Update: Small Aortic Annulus
The VIVA Trial: TAVR Versus SAVR in Patients With Severe Aortic Stenosis and Small Aortic Annuli
10/31/2023
Josep Rodés-Cabau, MD, PhD
"TAVR and SAVR represent a valid alternative for treating patients with aortic stenosis and small aortic annulus,” concluded Dr. Rodés-Cabau.
"TAVR and SAVR represent a valid alternative for treating patients with aortic stenosis and small aortic annulus,” concluded Dr. Rodés-Cabau.
"TAVR and SAVR represent a valid...
10/31/2023
Cath Lab Digest
Philippe Généreux, MD
aortic stenosis
Novel Research on Aortic Stenosis From egnite, Inc.’s Database Presented at Transcatheter Cardiovascular Therapeutics Conference 2023
10/25/2023
“This research is the first of its kind to look at such a large cohort of AS patients over a four-year span. Findings serve as a stark reminder of the poor prognosis associated with untreated AS irrespective of severity, suggesting patients...
“This research is the first of its kind to look at such a large cohort of AS patients over a four-year span. Findings serve as a stark reminder of the poor prognosis associated with untreated AS irrespective of severity, suggesting patients...
“This research is the first of...
10/25/2023
Cath Lab Digest
ShortCut device
Leaflet Modification
The ShortCut Pivotal Trial: A Dedicated Valve Leaflet Splitting Device
10/25/2023
Susheel K. Kodali, MD
The ShortCut leaflet splitting procedure can be done in anywhere from five to 10 minutes, says Dr. Susheel Kodali, and patients typically remain stable during the procedure.
The ShortCut leaflet splitting procedure can be done in anywhere from five to 10 minutes, says Dr. Susheel Kodali, and patients typically remain stable during the procedure.
The ShortCut leaflet splitting...
10/25/2023
Cath Lab Digest
Mohan EPLD Watchman LAAO
Clinical Trial Update: TAVR & LAAO
WATCH TAVR Trial Finds That Atrial Fibrillation Patients Undergoing TAVR and Watchman Procedures Together Have Similar Outcomes to Using Blood Thinners After TAVR
10/24/2023

Cleveland Clinic News

Cleveland Clinic News
The multicenter, randomized WATCH-TAVR trial set out to investigate the safety of implantation of the WATCHMAN 2.5 device at the time of TAVR and to compare the efficacy of WATCHMAN LAAO with contemporary medical therapy in this population of...
The multicenter, randomized WATCH-TAVR trial set out to investigate the safety of implantation of the WATCHMAN 2.5 device at the time of TAVR and to compare the efficacy of WATCHMAN LAAO with contemporary medical therapy in this population of...
The multicenter, randomized...
10/24/2023
Cath Lab Digest
Sapien 3 Valve (Edwards)
Clinical Trial Update: Sapien 3 THV
Five-Year Data From PARTNER 3 Trial Demonstrate Excellent Survival for Patients Receiving Edwards Sapien 3 Valve
10/24/2023

Edwards Lifesciences News

Edwards Lifesciences News
"The five-year follow-up findings from the PARTNER 3 trial reaffirm the clinical outcome benefits and bioprosthetic valve durability of SAPIEN 3 TAVR as a meaningful alternative to surgical therapy for low-risk severe, symptomatic AS...
"The five-year follow-up findings from the PARTNER 3 trial reaffirm the clinical outcome benefits and bioprosthetic valve durability of SAPIEN 3 TAVR as a meaningful alternative to surgical therapy for low-risk severe, symptomatic AS...
"The five-year follow-up...
10/24/2023
Cath Lab Digest
clinical trial update: aortic regurgitation
JenaValve Announces Late-Breaking Data From the ALIGN-AR Pivotal Trial Meeting Safety and Efficacy Endpoints
10/24/2023

JenaValve Technologies, Inc. News

JenaValve Technologies, Inc. News ...
The trial met prespecified non-inferiority criteria for its primary safety endpoint and primary efficacy endpoint. Outcomes were presented by Dr. Vinod Thourani (Piedmont Heart Institute, Atlanta, GA).
The trial met prespecified non-inferiority criteria for its primary safety endpoint and primary efficacy endpoint. Outcomes were presented by Dr. Vinod Thourani (Piedmont Heart Institute, Atlanta, GA).
The trial met prespecified...
10/24/2023
Cath Lab Digest
Benjamin Z. Galper, MD, MPH
referral pathways
The TAVR DELAY Registry: Rates of Early Referral to a Structural Heart Team in a Large Integrated Healthcare System
10/24/2023
Benjamin Z. Galper, MD, MPH, FACC, FSCAI
“TAVR is an amazing technology," says Benjamin Z. Galper, MD, MPH. "But for some reason, TAVR is not being disseminated in the population as widely as it should be, given that we have so many structural heart programs across the country. Why...
“TAVR is an amazing technology," says Benjamin Z. Galper, MD, MPH. "But for some reason, TAVR is not being disseminated in the population as widely as it should be, given that we have so many structural heart programs across the country. Why...
“TAVR is an amazing technology,"...
10/24/2023
Cath Lab Digest
Medtronic Evolut PRO
Clinical Trial Update: Self-Expanding THV
Medtronic Evolut TAVR Platform Outperforms Surgery With Sustained Valve Performance for Low-Risk Patients at Four Years
10/24/2023

Medtronic News

Medtronic News
Since the approval of TAVR in low-risk surgical patients, there is an ongoing need for evidence to better understand the intermediate and longer-term durability of TAVR devices of different designs.
Since the approval of TAVR in low-risk surgical patients, there is an ongoing need for evidence to better understand the intermediate and longer-term durability of TAVR devices of different designs.
Since the approval of TAVR in...
10/24/2023
Cath Lab Digest
OpSens SavvyWire
Clinical Trial Update: SavvyWire
OpSens Announces Positive Clinical Results From SAFE-TAVI Study With SavvyWire in Europe
10/24/2023

OpSens News

OpSens News
"SAFE-TAVI Clinical Study: SavvyWire Efficacy and Safety in TAVI Procedures" will be presented on Wed, Oct 25, at 10:09am PST, at Moderated Abstracts Station 2 – Emerging Clinical Science & Research, Hall A, Exhibition Level, Moscone South
"SAFE-TAVI Clinical Study: SavvyWire Efficacy and Safety in TAVI Procedures" will be presented on Wed, Oct 25, at 10:09am PST, at Moderated Abstracts Station 2 – Emerging Clinical Science & Research, Hall A, Exhibition Level, Moscone South
"SAFE-TAVI Clinical Study:...
10/24/2023
Cath Lab Digest
Prof. Anthony Walton, MBBS, FRACP, FCSANZ
Hemostasis & Bleeding Reduction
ACE-PROTAVI: Safety and Efficacy of Protamine in TAVI for Prevention of Bleeding Complications
10/24/2023
Anthony Walton, MBBS, FRACP, FCSANZ
“Our conclusion,” said Prof. Tony Walton, “was that routine protamine administration should be considered in all patients undergoing TAVI, unless a recent coronary intervention has been performed.”
“Our conclusion,” said Prof. Tony Walton, “was that routine protamine administration should be considered in all patients undergoing TAVI, unless a recent coronary intervention has been performed.”
“Our conclusion,” said Prof....
10/24/2023
Cath Lab Digest
Ong JIC May 2021
Research Focus
A Look at TAVR Research at TCT 2023
10/21/2023

From Cath Lab Digest's TAVR@TCT 2023 Newsroom

From Cath Lab Digest's TAVR@TCT 2023 ...
With several hotly anticipated late-breaking clinical trial results centering around transcatheter aortic valve replacement (TAVR), the 2023 TCT meeting, held October 23-26 in San Francisco, California, promises attendees a deep dive into the...
With several hotly anticipated late-breaking clinical trial results centering around transcatheter aortic valve replacement (TAVR), the 2023 TCT meeting, held October 23-26 in San Francisco, California, promises attendees a deep dive into the...
With several hotly anticipated...
10/21/2023
Cath Lab Digest
conference coverage
TAVR@TCT: 2023 Late-Breaking Clinical Trials Announced
09/20/2023

TCT News

TCT News
Cath Lab Digest's TCT 2023 Newsroom will provide a special focus on TAVR. The Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium will take place October 23-26 in San Francisco, California.
Cath Lab Digest's TCT 2023 Newsroom will provide a special focus on TAVR. The Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium will take place October 23-26 in San Francisco, California.
Cath Lab Digest's TCT 2023...
09/20/2023
Cath Lab Digest

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use